Amarillo Receives SBIR Grant to Develop Vaccine for Helicobacter Pylori

Amarillo Biosciences has received a Small Business Innovative Research (SBIR) grant from the NIH.

The SBIR grant is for $104,372 and will be used by Amarillo Biosciences to further develop a vaccine to combat Helicobacter pylori (H. pylori), a major cause of gastritis and gastroduodenal ulcer disease in humans.

H. pylori is a spiral-shaped bacterium that is found in the stomach of humans, where it causes more than 90 percent of duodenal ulcers and up to 80 percent of gastric ulcers. In developing countries, infection is frequently symptomatic and is thought to be responsible for the high incidence of gastric cancer in those areas. The cost and expense of pharmacological intervention is beyond the means of most of the world's population. A safe and effective vaccine, or affordable therapy could provide significant relief to the infected population.